Clinical TrialJul 22, 2026, 07:07 AM
Radiopharm RAD204 Phase 1 Shows Durable Partial Response
AI Summary
Radiopharm Theranostics announced positive initial clinical results from the first two patients in the third cohort of its Phase 1 trial for RAD204, an investigational PD-L1-targeted radiotherapeutic. The first patient achieved a RECIST-confirmed durable Partial Response, remaining progression-free beyond seven months, while the second patient showed early tumor shrinkage and remains progression-free. RAD204 was generally well-tolerated with no dose-limiting toxicities observed, reinforcing its safety profile at the highest dose level.
Key Highlights
- First patient achieved a RECIST-confirmed durable Partial Response, remaining progression-free beyond seven months.
- Patient 1 showed a 43% reduction in target lesions after Dose 2, maintained through Dose 3.
- Patient 2 demonstrated an early 7% reduction in target lesions after the first treatment cycle.
- RAD204 was generally well-tolerated with no dose-limiting toxicities observed across all dosing cohorts.
- Limited kidney uptake (cumulative 8.1 Gy across four cycles in Patient 1) supports dose escalation.
- RAD204 is a PD-L1-targeted lutetium-177 nanobody radiotherapeutic.
Price Impact
More from RADX